Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › NantHealth Signs Reseller Deal With Oncotest-Teva for GPS Cancer in Israel

NantHealth Signs Reseller Deal With Oncotest-Teva for GPS Cancer in Israel

Dec 06, 2016
|
staff reporter

NEW YORK (GenomeWeb) – NantHealth announced today that it has signed an exclusive reseller agreement with Teva Pharmaceuticals subsidiary Oncotest-Teva to distribute its GPS Cancer molecular test in Israel.

Under the terms of the deal, Oncotest-Teva will be the only distributor of GPS Cancer to clinicians in that country. Further terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
22
Featured Webinar

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

What's Popular?

In Cancer

  1. NeoGenomics to Grow Pharma, Informatics Divisions Through CDx Agreements, Acquisitions

    Premium

  2. Caris Shares Data for AI-Driven Tumor Origin Prediction, Hinting at Diagnostic, Patient Benefit

    Premium

  3. Todos Medical Obtains $3.4M Investment From Yozma Group Korea

  4. OncoLab Diagnostics Targets Cancer Recurrence Monitoring with CTC-Derived Biomarker Assay

    Premium

  5. Oppenheimer Initiates Coverage of DermTech With Outperform Rating

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.